Defence Therapeutics Inc. (OTCMKTS:DTCFF) Short Interest Up 1,266.7% in January

Defence Therapeutics Inc. (OTCMKTS:DTCFF) was the target of a large growth in short interest in January. As of January 31st, there was short interest totalling 4,100 shares, a growth of 1,266.7% from the January 15th total of 300 shares. Based on an average daily volume of 64,900 shares, the days-to-cover ratio is presently 0.1 days.

Defence Therapeutics Price Performance

Shares of DTCFF remained flat at $0.80 during trading hours on Friday. 4,000 shares of the stock were exchanged, compared to its average volume of 34,267. The firm has a 50-day moving average of $0.50 and a 200 day moving average of $0.47. Defence Therapeutics has a 1-year low of $0.27 and a 1-year high of $1.45.

Defence Therapeutics Company Profile

Defence Therapeutics Inc engages in development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on development of vaccine for infectious disease and virus utilizing the ACCUMTM platform for drug delivery and effective treatments.